Jump Financial’s Design Therapeutics DSGN Stock Holding History

Jump Financial’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,000	Closed	-$59.2K	–	1740
2024 Q3	$59.2K	Sell	11,000 -9,087	-45%	-$42.7K	﹤0.01%	1552
2024 Q2	$67.3K	Buy	+20,087	New	+$78.3K	﹤0.01%	1672
2023 Q4	–	Sell	-46,700	Closed	-$110K	–	1890
2023 Q3	$110K	Buy	46,700 +34,561	+285%	+$161K	﹤0.01%	1663
2023 Q2	$76.5K	Sell	12,139 -46,661	-79%	-$286K	﹤0.01%	1688
2023 Q1	$339K	Buy	58,800 +28,400	+93%	+$212K	0.01%	1062
2022 Q4	$312K	Buy	+30,400	New	+$412K	0.02%	1016

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jump Financial's DSGN Position: Q4 2024 in Review

Jump Financial sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 11,000 shares — an estimated $59.2K sold.

Jump Financial first reported a position in DSGN in Q4 2022 and held it in 6 quarters. The position peaked at $339K in Q1 2023. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

Jump Financial reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
Jump Financial sold 11,000 Design Therapeutics shares in Q4 2024, an estimated $59.2K.
Jump Financial first reported a position in Design Therapeutics in Q4 2022 and held it in 6 quarters.
Jump Financial's Design Therapeutics position peaked at $339K in Q1 2023.
95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.